Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.
Also called NCT02967237
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 136 participants
- Sponsor
- Registry
-
NCT02967237 -
2015-002416-33
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT02967237. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01-04 (registry gives no type); primary completion 2017-07-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
- Acronym
- Transition II
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin glargine (U300)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02967237- Content hash
ea4414a24a855737be37805ede423174c3ef44a82798ea6cad066000756beeb1